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Pancreatic b cells are of great interest for the treat-
ment of type 1 diabetes. A number of strategies
already exist for the generation of b cells, but a gen-
eral approach for reprogramming nonendodermal
cells into b cells could provide an attractive alterna-
tive in a variety of contexts. Here, we describe a step-
wise method in which pluripotency reprogramming
factors were transiently expressed in fibroblasts
in conjunction with a unique combination of solu-
ble molecules to generate definitive endoderm-like
cells that did not pass through a pluripotent state.
These endoderm-like cells were then directed to-
ward pancreatic lineages using further combina-
tions of small molecules in vitro. The resulting
pancreatic progenitor-like cells could mature into
cells of all three pancreatic lineages in vivo, including
functional, insulin-secreting b-like cells that help to
ameliorate hyperglycemia. Our findings may there-
fore provide a useful approach for generating large
numbers of functional b cells for disease modeling
and, ultimately, cell-based therapy.
INTRODUCTION
Type 1 diabetes results from autoimmune destruction of the
insulin-secreting b cells within pancreatic islets. This disease
typically affects children and young adults and requires frequent
glucosemonitoring and life-long insulin administration for proper
management. In conjunction with new strategies to induce
immune tolerance, transplantation of healthy islet and b cells to
replace lost cells may represent a ‘‘cure’’ for the disease. How-
ever, a primary challenge remains in the scarcity of functional,
glucose-responsive b cells.
Stem cells may provide an unlimited source of functional
b cells and would facilitate biomedical research and drug dis-
covery. Stepwise conditions that recapitulate developmental
signaling have been devised to differentiate pluripotent stem
cells through a definitive endoderm stage into functional pancre-
atic b cells (D’Amour et al., 2006, Jiang et al., 2007). Direct
reprogramming from non-b cells, such as acinar cells or hepato-228 Cell Stem Cell 14, 228–236, February 6, 2014 ª2014 Elsevier Inccytes, has also been used to generate pancreatic b-like cells
(Zhou et al., 2008, Ferber et al., 2000).
Conventional direct b-cell reprogramming is faster and more
efficient than preparing induced pluripotent stem cells (iPSCs).
However, a general approach to converting nonendoderm cells,
such as fibroblast cells across the germ-layer boundary toward
an endoderm-b cell lineage, has not been developed yet. Cell
types derived from the endoderm lineage, such as acinar cells
or hepatocytes, may be easier to reprogram into the b cell line-
age owing to their similarity. However, applying these methods
to cell-based therapy or in vivo therapy may be challenging
due to the practicality of starting cells or the virus delivery sys-
tem. In addition, b-like cells generated by conventional direct re-
programming are postmitotic and have very limited regenerative
ability. Thus, pancreatic progenitor cells may be a better cell
source for transplantation because of their proliferation and dif-
ferentiation potential.
Previously, we developed a strategy for direct lineage-specific
reprogramming (Efe et al., 2011, Kim et al., 2011; Li et al., 2013).
In the current study, we applied this method with a unique
combination of soluble molecules to generate definitive endo-
derm-like cells from mouse fibroblasts. The endoderm-like cells
expressed typical endodermal markers and could differentiate
into pancreatic lineages that exhibited characteristic properties
in vitro and in vivo. Our findings may provide a useful approach
for generating large numbers of functional b cells for disease
modeling and ultimately cell therapy.RESULTS
Conversion of Fibroblasts into Definitive Endoderm-like
Cells
We used doxycycline (Dox)-inducible secondary mouse embry-
onic fibroblasts (MEFs) (Wernig et al., 2008) to enable expression
of the conventional four iPSC factors (Oct4, Sox2, Klf4, and
c-Myc) with precise temporal control. MEFswere prepared using
standard procedures and used for reprogramming after three or
four passages. Although endoderm cells may exist in starting
MEF populations, we did not observe any contamination of these
cells in our cultures.
To extend and test the iPSC-factor-based lineage-specific
reprogramming paradigm to endoderm, we devised a two-step
process to directly reprogram secondary MEF cells into defini-
tive endoderm-like cells (DELCs). The first step (Step I) was.
Figure 1. Initial Approach for Reprogramming MEFs into Pancreatic b-like Cells
(A) Scheme of the initial approach. Med-IV contains laminin, nicotinamide, and B27 etc., as described (Schroeder et al., 2006). (B) Immunostaining and (C) gene
expression of definitive endodermmarkers Sox17, CXCR4, Foxa2, and Cerberus 1 on day 12. NGFP1 iPSC-derived definitive endoderm-like cells (DE) were used
as a positive control. (D) Immunostaining and (E) gene expression of pancreatic progenitor markers Pdx1, Hnf6, Pax6, and Nkx6.1 on day 18. (F) Immunostaining
of pancreatic b cell markers insulin (Ins) and C-peptide (C-pep) on day 27. (G) Gene expression analysis of Ins1 and Ins2 from day 18 to day 27. Results in (C), (E),
and (G) are the average of at least three independent experiments. *p < 0.05, **p < 0.01. See also Figure S1.
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with 4 mg/ml Dox to initiate epigenetic activation. The second
step (Step II) was culturing the epigenetically activated cells in
Med-II supplemented with 50 ng/ml Activin A and 1 mM LiCl
(Activin/Li) (Li et al., 2011). Sox17 and Foxa2, two relatively
specific markers for definitive endoderm, were examined by
immunostain at the end of Step II. By testing different durations
of Steps I and II, we found that 6 days in Step I followed
by 6 days in Step II was an effective condition to generate
Sox17+/Foxa2+ cells (hereafter referred to as DELCs) with
relatively high efficiency.
We hypothesized that transcriptional activity downstream of
lineage-specific signals, in conjunction with iPSC factors that
erase the epigenetic identity of the starting cell during early re-
programming, may help set up lineage-specific transcriptional
programs. To test this, we compared conditions in which defin-
itive endoderm induction factors (Activin/Li) were added to fibro-
blasts either after (Approach 1) or during (Approach 2) iPSC
factor expression (Figure S1A). Notably, Approach 2 greatlyCeincreased themRNA levels of Sox17 and Foxa2 and the percent-
age of Sox17+/Foxa2+ colonies (Figures S1B–S1D) over what
was observed in Approach 1. With the use of Approach 2,
iPSC factor expression in the presence of Activin/Li for 6 days
followed by Activin/Li treatment for another 6 days caused
high induction of other definitive endoderm marker genes,
including Cerberus 1 (Cer) and C-X-C chemokine receptor type
4 (Cxcr4), in addition to Sox17 and Foxa2 (Figures 1B and 1C).
These results supported our initial hypothesis.
Next we tested if DELCs possess differentiation potential
toward pancreatic lineages. We attempted their differentiation
by adopting published pancreatic differentiation conditions
(D’Amour et al., 2006, Li et al., 2011). Notably, like definitive
endoderm cells derived from mouse embryonic stem cells
(mESCs), our DELCs could also give rise to cells expressing spe-
cific markers for pancreatic progenitors, including pancreatic
and duodenal homeobox gene-1 (Pdx1), hepatocyte nuclear fac-
tor-6 (Hnf6), paired-box gene 6 (Pax6), and NK homeobox factor
6.1 (Nkx6.1), as examined by immunostaining and real-time PCRll Stem Cell 14, 228–236, February 6, 2014 ª2014 Elsevier Inc. 229
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progenitor-like cells (PPLCs) in vitro gave rise to insulin+/
C-peptide+ cells (Figures 1F and 1G). Our results showed that
DELCs could differentiate to pancreatic b-like cells in a process
similar to what has been previously observed with definitive
endoderm cells derived from mESCs.
Despite this success, the efficiency of generating pancreatic-
like cells was low, although similar to differentiation of mESCs
using the same conditions. For example, only about 5% and
10% of cells were positive for either Nkx6.1 or Pdx1, respec-
tively, and only about 1%were Pdx1+/Nkx6.1+. Further differen-
tiation in vitro gave rise to <0.1% insulin expressing cells that did
not respond well to high glucose stimulation. These results indi-
cated that the lineage induction conditions could be further
improved, so we then focused on optimizing inductive condi-
tions by small molecules.
Identification of Combinations of Small Molecules that
Enhance Generation of PPLCs
b cell formation and maturation are impaired in Nkx6.1 null
mutant mice and could be restored upon re-expression of
Nkx6.1 in multipotential Pdx1+ pancreatic progenitors (Nelson
et al., 2007). In other studies, Pdx1+/Nkx6.1+ pancreatic pro-
genitor cells differentiated from human embryonic stem cells
(ESCs) could give rise to all pancreatic cell lineages, including
glucose-responsive, insulin-secreting cells, in vivo (Kelly et al.,
2011, Rezania et al., 2013). These studies suggest that dual
expression of Pdx1 and Nkx6.1may predict the ability of pancre-
atic progenitors to give rise to functional b cells. We therefore set
out to identify conditions that induce Pdx1+/Nkx6.1+ PPLCs
from our reprogrammed DELCs.
We screened a known drug collection of 400 compounds.
Med-III (DMEM supplemented with 1xB27, 2 mM Glutamax)
was used as a basal condition and double staining of Pdx1
and Nkx6.1 4 days postinduction was used as a readout. This
was our third step (Step III) of pancreatic induction. Several pri-
mary hits that could increase Pdx1 and/or Nkx6.1 expression
were further characterized. Confirmed hits included retinoic
acid (RA, a RAR agonist), A83-01 (a TGF-b receptor inhibitor),
2-phospho-L-ascorbic acid (pVc), and LDE225 (a Hedgehog
pathway inhibitor) (Figures S2A and S2B). After testing various
small molecule combinations, we determined that a much
improved pancreatic induction was achieved by treating DELCs
with 2 mM RA, 1 mM A83-01, 2 mM LDE225, and 280 mM pVc for
1 day, and then 1 mMA83-01, 2 mM LDE225, and 280 mM pVc for
another 3 days. Under these conditions, the pancreatic progen-
itor markers Pdx1, Nkx6.1, Hnf6, Pax6, and Sox9 were highly
expressed and colocalized (Figure 2B). About 35% of the cells
expressed Pdx1, and about 30% of the cells expressed
Nkx6.1, a 2.5-fold and 5-fold increase, respectively, over the
initial approach. More importantly, about 8% of the cells were
Pdx1+/Nkx6.1+, a 7-fold increase over the initial approach.
qRT-PCR analysis further confirmed expression of Pdx1,
Nkx6.1, Hnf6, and Pax6 during the pancreatic induction process
(Figure 2C). These results suggest that this combination of small
molecules promoted differentiation of DELCs into Pdx1+/
Nkx6.1+ PPLCs.
We next hypothesized that overlapping lineage-specific
patterning conditions with early reprogramming based on small230 Cell Stem Cell 14, 228–236, February 6, 2014 ª2014 Elsevier Incmolecules would enhance pancreatic induction. We further
screened our known drug collection during the Step I and II
inductions, followed by double staining for Pdx1 and Nkx6.1 at
the end of Step III (day 16) as a readout. Remarkably, several
small molecules, when applied during Step I and/or Step II,
greatly enhanced pancreatic induction. Particularly, 1 mM Bix-
01294 (a G9a inhibitor), when added from day 0 to day 6, and
280 mM pVc, when added from day 0 to day 12, increased the
number of Pdx1+/Nkx6.1+ colonies to about 3-fold and 4-fold,
respectively (Figures 2D and 2E). Further testing revealed that
the combination of 1 mM Bix-01294 (added from day 0 to day
6) and 280 mMpVc (added from day 0 to day 12) generated about
an 8-fold increase in Pdx1+/Nkx6.1+ colonies (Figures 2D and
2E). Interestingly, treatment with Bix and/or pVc did not alter
the numbers of Sox17 and Foxa2 single-positive and double-
positive cells.
Employing these advanced conditions (Figure 2A), we
analyzed the cells on day 12 (DELC stage) and day 16 (PPLC
stage) in greater detail. On day 0, 23 104MEF cells were seeded
in a well of a 24-well plate. On day 12, the cell number in the well
was about 93 105. Immunostaining showed that definitive endo-
derm marker genes, Sox17, Foxa2, Cer, and Cxcr4, were highly
expressed (Figure 2F). FACS analysis revealed that the percent-
age of Sox17+/Foxa2+ cells was about 54%. Importantly, we
found that DELCs could be isolated and expanded in Activin/Li
for over 1 month in serial multiple passages (Figures S2C and
S2D) without losing their potential to differentiate into pancre-
atic progenitors (Figure S2E). This expansion translates into an
approximately 65,000-fold increase in cell number. On day 12,
we also examined some nonendodermal markers. About
0.46% of cells were Brachyury/T+ (which indicates the presence
of an early mesoderm marker gene), while Sox1+ cells (which
indicate the presence of an early neuroectoderm marker gene)
were not detected (Figure S4C). On day 16, the cell number
increased to about 1.1 3 106 per well. FACS analysis showed
about 30% of the cells are PDX1+/NKX6.1+ Some endocrine
progenitor marker genes, namely Ngn3, Neurod1, and Nkx2.2,
were also detected at low levels (Figures S2F and S2G). How-
ever, we have not yet found an appropriate condition to expand
PPLCs in a prolonged manner. On day 16, we also examined
some nonpancreatic markers. About 0.66% of cells were
CDX2+ (indicative of an intestinal marker gene) and about
0.87% of cells were positive for GATA4 (a midstage mesoderm
marker gene), while those positive for Tuj1 (a neuronal marker
gene) and MAP2 (another neuronal marker gene) were not
detected (Figures S4D and S4E).
PPLCs Can Be Further Differentiated into Mature
Pancreatic-like Cells
To determine whether PPLCs generated by the above conditions
can be further differentiated into mature pancreatic-like cells
(PLCs), we treated PPLCs with Med-IV containing laminin, nico-
tinamide, B27, etc. as previously reported (Schroeder et al.,
2006). After 9 days of culture inMed-IV, a small population (about
0.5%) of insulin and C-peptide double-positive cells was
detected. To improve efficiency of pancreatic maturation, we
screened our known drug collection in this fourth step (Step IV)
with double staining of insulin and Pdx1 on day 25 as a readout.
We found that 5 mM SB203580 and 280 mM pVc significantly.
Figure 2. Identification of Small Molecule Conditions that Enhance Generation of PPLCs
(A) Scheme of the advanced approach. Red indicates small molecules that significantly improved induction efficiencies.
(B) Immunostaining of pancreatic progenitor markers Pdx1, Hnf6, Sox9, Pax6, and Nkx6.1 on day 16. Cells were treated with the combination of four small
molecules (RA, A83-01, LDE225, and pVc) from day 12 to day 16.
(C) Gene expression analysis of markers during the pancreatic progenitor induction process by qPCR. Results are the average of three independent experiments.
*p < 0.05, **p < 0.01.
(D) Immunostaining of Pdx1 and Nkx6.1 on day 16.
(E) Pdx1+/Nkx6.1+ colony numbers under indicated conditions on day 16. Four thousand cells were seeded into each well of 24-well plate on day 0. Results are
the average of three independent experiments. *p < 0.05.
(F) Immunostaining of Sox17, CXCR4, Foxa2, and Cerberus 1 on day 12.
In (D), (E), and (F), Bix (Bix-01294) at 1 mMwas added from day 0 to day 6 and pVc (2-Phospho-L-ascorbic acid trisodium salt) at 280 mMwas added from day 0 to
day 12. See also Figures S2, S3, and S4.
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ually and further enhanced the insulin+/Pdx1+ cell population
(about 2%) when combined (Figure 3A). Insulin and C-peptide
double staining confirmed that the insulin was produced by
the cells and not by absorption from Med-IV (Figure 3A). Gene
expression analysis of insulin, Pdx1, and Nkx6.1 showed
consistent results (Figure 3B). Glucagon-producing pancreatic
a-like cells, somatostatin-producing pancreatic d-like cells,
and amylase-producing pancreatic acinar-like cells were alsoCedetected on day 25 (Figure 3C). Importantly, endocrine-like cells
produced only one hormone, a defining characteristic of mature
pancreatic endocrine cells. Insulin-positive and C-peptide-posi-
tive b-like cells were also Nkx6.1-positive and Pdx1-positive
(Figure 3C). Functional analysis showed that b-like cells could
release insulin and C-peptide in response to glucose, tolbuta-
mide, and IBMX stimulation. However, their response to glucose
stimulation was impaired when compared to that of native
mouse islets (Figure 3D). Thus, these differentiated PPLCsll Stem Cell 14, 228–236, February 6, 2014 ª2014 Elsevier Inc. 231
(legend on next page)
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including functional insulin-secreting b-like cells.
iPSCs Were Not Generated During the Reprogramming
of Fibroblasts to PLCs
Generating iPSCs with the secondary MEFs requires at least
9 days of Dox treatment with LIF, followed by an additional 7–
10 days of culture, as confirmed by expression of a knockin
GFP reporter for Nanog, a pluripotency gene (Wernig et al.,
2008). Using our method, we did not detect any Nanog-GFP-
positive cells during the whole process from MEFs to PLCs,
which we assessed via time-lapse imaging (Figures S3B–S3D).
This finding is consistent with our previous studies on direct car-
diac, neural, and endothelial cell reprogramming (Efe et al., 2011;
Kim et al., 2011; Li et al., 2013) and confirmed that our approach
could directly reprogram MEFs to DELCs and eventually PLCs
that bypassed the iPSC stage.
In Vivo Characterizations of PPLCs
To assess PPLC function in vivo, we transplanted PPLCs under
the kidney capsule in immunodeficient NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice induced to become hyperglycemic
by intraperitoneal injection of Streptozocin (STZ). Each recipient
received a renal subcapsular transplant of 300 native mouse
islets, 3 3 106 PPLCs, or 3 3 106 MEF cells. Untreated normal
and STZ-only-treated NSG mice were used as controls.
In the untreated group, blood glucose levels were unchanged,
as expected (Figure 4A). In the STZ-only group, glucose levels
increased gradually and peaked by the end of the fourth week.
In the group transplanted with mouse native islets, diabetic
mice almost achieved normal glycemia 1 week after transplanta-
tion, which served as positive control. In the group transplanted
with PPLCs derived from MEFs, diabetic mice exhibited a
transient increase in glucose levels within the first week, which
then decreased gradually, approaching levels in normal mice.
Importantly, these mice returned to diabetic glucose levels after
nephrectomies of kidneys transplanted with PPLCs reprog-
rammed from MEFs, confirming a direct link between trans-
plantation of the PPLCs and amelioration of hyperglycemia. In
contrast, in the groups transplanted with PPLCs derived from
mouse iPSCs, either by our own optimized differentiation condi-
tions or those previously published (D’Amour et al., 2006; Li
et al., 2011; Nostro et al., 2011), significant amelioration of hyper-
glycemia was not observed. In the group transplanted with
MEFs, glucose levels increased similarly to the STZ-only group.
Eight weeks posttransplantation, we analyzed glucose-stimu-
lated insulin secretion (GSIS) and conducted a glucose tolerance
test (GTT). The PPLCs that were reprogrammed fromMEFs gaveFigure 3. PPLCs Can Be Further Induced into PLCs
(A) Immunostaining of Pdx1/insulin and insulin/C-peptide on day 25 after treatme
salt) at 280 mM from day 16 to day 25.
(B) Gene expression analysis of Ins1, Ins2, Pdx1, and Nkx6.1 by qPCR. Cells tr
independent experiments. *p < 0.05, **p < 0.01.
(C) Immunostaining of pancreatic cell markers insulin, C-peptide, Glucagon, Som
(D) Insulin and C-peptide release on day 25. Fold stimulation of insulin and C-pe
secretion agonists. Native mouse islets served as a control. Glu, 16.7mM D-glu
Results are the average of four independent experiments.
See also Figures S3 and S4.
Cerise to functional glucose-responsive, insulin-secreting cells
in vivo, asmeasured by levels of serum insulin and blood glucose
before and after glucose stimulation (Figures 4B and 4C).
Subsequently, the left kidneys were surgically removed
for immunohistochemistry analysis. In kidney capsules en-
grafted with PPLCs reprogrammed from MEFs, we identified
glucagon-producing pancreatic a-like cells, insulin-producing
pancreatic b-like cells, somatostatin-producing pancreatic
d-like cells, amylase-producing pancreatic acinar-like cells,
and Pdx1+/Ck19+ pancreatic ductal-like cells (Figure 4D). The
insulin-positive cells were Pdx1-positive and Nkx6.1-positive
(Figure 4E). Importantly, these endocrine-like cells were nearly
all singly hormonal, and bihormonal cells were rarely detected,
consistent with our in vitro findings (Figure 4E). In contrast, we
detected much fewer PLCs in the groups transplanted with
PPLCs derived frommouse iPSCs (by either our or published dif-
ferentiation conditions) and no PLCs in theMEF group. As shown
in Figure 4F, endocrine cell numbers in histological sections of
each group were quantified. The b-like cells in the group trans-
planted with PPLCs reprogrammed from MEFs are about 50%
of islet group.
These results showed that PPLCs could mature into cells of all
three pancreatic lineages, including functional, insulin-secreting
b-like cells that help to ameliorate hyperglycemia in vivo.
DISCUSSION
Our results demonstrate that functional DELCs and PPLCs can
be generated from fibroblasts without going through a pluripo-
tent state. Our approach is faster and potentially safer than
methods that have iPSCs as an intermediate step and has the
potential to provide sufficient numbers of functional progenitor
cells for transplantation and other applications. In addition, we
provide findings related to how lineage specification may be
achieved and facilitated.
First, we found that providing the lineage specification signal
at the beginning of iPSC-factor-mediated epigenetic activation
improved the efficiency of direct definitive endoderm reprogram-
ming. This observation suggests that transcriptional programs
downstream of lineage specification signals specifically redirect
iPSC-factor-mediated epigenome remodeling before an inter-
mediate stage is established. Furthermore, this suggests that
providing early lineage specification signals ensures that plurip-
otent cells are not generated.
We also found that, while Pdx1 or Nkx6.1 single-positive cells
could be readily generated from DELCs by known conditions,
they rarely coexpressed the other master pancreatic specifica-
tion gene and consequently failed to mature into terminallynt with SB (SB203580) at 5 mM and pVc (2-Phospho-L-ascorbic acid trisodium
eated with dissolvent were used as control. Results are the average of three
atostatin, Amylase, Pdx1, and Nkx6.1 on day 25.
ptide release over the respective basal condition for glucose and other insulin
cose; TOL, 100 mM tolbutamide; IBMX, 0.5 mM 3 isobutil-1-methylxanthine.
ll Stem Cell 14, 228–236, February 6, 2014 ª2014 Elsevier Inc. 233
Figure 4. In Vivo Characterizations of
PPLCs
(A) Blood glucose level of normal and STZ-induced
diabetic mice without grafts or transplanted with
PPLCs, MEFs, or islets. Under anesthesia, the left
kidney of diabetic mice received a renal subcap-
sular transplant of 300 native mouse islets in 30 ml
Matrigel (Islet, n = 4), 3 3 106 PPLCs re-
programmed from MEFs (MEF-derived PPLC, n =
10), 3 3 106 NGFP1 mouse iPSC-derived PPLCs
by our own optimized differentiation conditions
(iPSC-derived PPLC1, n = 6), 3 3 106 NGFP1
mouse iPSC-derived PPLCs by published differ-
entiation conditions (iPSC-derived PPLC2, n = 6),
or 3 3 106 secondary MEF cells (MEF, n = 6).
Untreated normal mice (Norm, n = 4) and mice
treated with STZ only (STZ, n = 4) were controls.
Eight weeks after transplantation, the left kidneys
were surgically removed.
(B) Glucose-stimulated insulin secretion (GSIS).
Mice were fasted overnight, D-glucose (3 g/kg
body weight) was injected intraperitoneally, and
serum insulin levels of each group were measured
before and 30 min after glucose stimulation.
(C) Intraperitoneal glucose tolerance tests
(IPGTTs). Mice were treated as in (B) and blood
glucose levels were measured at 0, 15, 30, 60, 90,
and 120 min after glucose stimulation.
(D and E) Immunofluorescence staining of kidneys
engrafted with MEF-derived PPLCs.
(F) Quantification of endocrine cell numbers of
mice from MEF, PPLC, and islet grafts. For each
experimental group, endocrine cells of four mice
were counted and averaged as described in the
Experimental Procedures.
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come this challenge, we devised a screening strategy to uncover
combinations of small molecules that could generate Pdx1+/
Nkx6.1+ cells. Remarkably, we found that a combination of
four small molecules (RA, A83-01, LDE225, and pVc), in the
absence of growth factors used in other protocols (such as
FGF10 and EGF), could effectively induce Pdx1+/Nkx6.1+ cells
from DELCs, increasing the production of Pdx1+/Nkx6.1+ cells
about 7-fold. While RA and Hedgehog pathway inhibitor are
known to induce pancreatic differentiation, the other two small234 Cell Stem Cell 14, 228–236, February 6, 2014 ª2014 Elsevier Inc.molecules—and their synergistic ability
to induce Pdx1+/Nkx6.1+ cells when
combined—have not, to our knowledge,
been reported before. Thus, dissection
of how inhibition of the TGF-b/Activin-A
pathway by A83-01, and the pleiotropic
signaling pathways triggered by pVc
exposure, contributes to pancreatic
specification is worthwhile.
Additionally, we explored whether
influencing early steps in lineage induc-
tion might significantly impact later
specification steps. To date, efforts to in-
fluence lineage induction to a particular
stage of development or differentiationhave mostly focused on the step immediately preceding the
particular stage and overlooked earlier steps. To further improve
pancreatic cell induction (the third step in our reprogramming),
we screened for new small molecules during the first two steps
of reprogramming toward definitive endoderm cells. Here we
used double staining of Pdx1/Nkx6.1 as a final readout after
the third step. Two small molecules, Bix-01294 and pVc, were
found to further increase the number of Pdx1+/Nkx6.1+ cells
when used at the first two steps. Notably, treatment with Bix-
01294 and pVc during the first two steps did not affect the
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day 12. This suggests that until we better understand the steps
and identification of more predictive markers in an early stage,
using general markers of the early developmental stage may
have limitations.
Importantly, we found that Bix-01294 and pVc could promote
human ESC differentiation into Pdx1+/Nkx6.1+ pancreatic pro-
genitors. As shown in Figures S2H and S2I, both Bix-01294
and pVc increased the number of Pdx1+/Nkx6.1+ colonies,
respectively, and their combination had a synergistic effect.
This result indicated that our findings in mouse cells might trans-
late to similar mechanisms in human cells.
We also carried out screens for small molecules that may pro-
mote pancreatic b-cell maturation. SB203580 and pVc strongly
and synergistically increased the number of insulin+/Pdx1+
cells. These small molecules facilitated reprogramming and
also provided chemical tools for further mechanistic studies.
Finally, we tested the developmental potential of our PPLCs
in vivo. PPLCs generated from MEFs by our advanced
approach efficiently generated all three pancreatic lineages,
including functional insulin secreting b-like cells, and amelio-
rated hyperglycemia in vivo. The PPLCs reprogrammed from
MEFs appeared to be more functional than the PPLCs derived
from mouse iPSCs. These results highlight the important roles
of these small molecules and the therapeutic potential of our
approach.
EXPERIMENTAL PROCEDURES
Direct Reprogramming of Fibroblasts into DELCs
Dox-inducible secondary MEFs were plated at 13 104 cells/cm2 and cultured
in MEFmedium for an additional day. The medium was then changed to Med-I
supplemented with 4 mg/ml Dox, 50 ng/ml Activin A, and 1mM LiCl for the indi-
cated time. Thereafter, themediumwas changed toMed-II supplementedwith
50 ng/ml Activin A and 1mM LiCl for the indicated time. Detailed protocols can
be found in Supplemental Experimental Procedures.
Differentiation of DELCs to PPLCs
DELCswere further cultured inMed-III and treatedwith 2 mMRA, 1 mMA83-01,
2 mM LDE225, and 280 mM pVc for 1 day, and then treated with 1 mM A83-01,
2 mM LDE225, and 280 mM pVc for another 3 days. Detailed protocols can be
found in Supplemental Experimental Procedures.
miPSC Culture and Differentiation
NGFP1 mouse iPSCs were cultured on MEF feeder cells in iPSC medium.
Pancreatic differentiation was performed with a published differentiation
protocol (D’Amour et al., 2006; Li et al., 2011; Nostro et al., 2011) with minor
modifications or with our own optimized differentiation protocol. Briefly,
our differentiation protocol involved seeding trypsinized NGFP1 mouse iPSCs
(20,000 cells/ml) in Med-II in Petri dishes for 2 days. Then EBs were collected
by brief centrifugation and resuspended inMed-II supplemented with 50 ng/ml
Activin A, 2 mM LiCl, and 280 mM pVc for another 2 days. After that, the cells
were trypsinized and replated (50,000 cells/cm2) on Matrigel-coated dishes in
Med-III and treatedwith 2 mMRA, 1 mMA83-01, 2 mMLDE225, and 280 mMpVc
for 1 day, and then treated with 1 mM A83-01, 2 mM LDE225, and 280 mM pVc
for another 3 days. Detailed protocols can be found in Supplemental Experi-
mental Procedures.
Transplantation Assay
Male, 8- to 10-week-old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
were injected i.p. with 35 mg/kg STZ daily for 4 days. Mice were considered
to be diabetic if blood glucose measurements were > 300 mg/dl for 4
consecutive days, after which they were used as transplant recipients. Under
anesthesia, the left kidneys of diabetic mice received a renal subcapsularCetransplant of 300 native mouse islets in 30 ml Matrigel (Islet, n = 4), 3 3 106
PPLCs reprogrammed from MEFs (MEF-derived PPLC, n = 10), 3 3 106
NGFP1 mouse iPSCs derived PPLCs by our own optimized differentiation
conditions (iPSC-derived PPLC1, n = 6), 33 106 NGFP1 mouse iPSC-derived
PPLCs by the published differentiation conditions (iPSC derived PPLC2, n =
6), or 3 3 106 secondary MEF cells (MEF, n = 6). Untreated normal mice
(Norm, n = 4) and mice treated with STZ only (STZ, n = 4) were used as
controls. Nonfasting blood glucose levels were measured weekly after
transplantation for 10 weeks. At the end of 8 weeks, glucose-stimulated insu-
lin secretion assay and intraperitoneal glucose tolerance tests were carried
out. Right after that, the left kidneys were surgically removed for immunohis-
tochemistry analysis. Detailed protocols can be found in the Supplemental
Experimental Procedures. All animal work was approved by the institutional
IACUC committee.
Immunohistochemistry
Kidneys were fixed in 4% paraformaldehyde and used for paraffin section and
cryosection. Kidneys were transversally sectioned and stained with primary
antibodies. Then, the antigen-primary antibody immune complex was visual-
ized with fluorescent secondary antibodies. Cell nuclei were counterstained
with DAPI. To quantify endocrine cell numbers of mice from MEF, PPLC,
and islet grafts, the endocrine cells were counted in four sections of a mouse
and these were averaged to obtain the endocrine cell numbers of the mouse.
For each group, four mice were averaged.
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